February 3, 2014 | Dicerna Pharmaceuticals, based in Watertown, MA, pulled in $90 million last week in its initial public offering. Dicerna is working on RNA interference-based therapies, beginning with indications for liver disease, various cancers, and primary hyperoxaluria, a genetic disease that can lead to kidney failure – all currently in preclinical phases. Dicerna's share price rose over 200% over the course of the day, the largest first-day gain for any company since 2005, demonstrating an appetite for gene silencing technologies among investors. Boston Globe